Abstract:

Objective To explore the clinical value and safety of PDI inhibitor combined with furoquantinib and TAS-102 in the treatment of advanced colorectal cancer. Methods This study is a retrospective analysis， collected a total of 30 late stage colorectal cancer cases that failed standard treatment. Among the 30 case， 12 cases were set as the observation group， and 18 cases were set as the control group. The observation group was treated with PD1 inhibitor combined with furoquantinib and TAS-102， while the control group was treated with PD1 inhibitor combined with furoquantinib. PD1 inhibitors include Xindilizumab 200 mg， Tirelizumab 200 mg， or Sepalizumab 240 ng. 3 ~ 5 mg Furoquantinib is received orally for two weeks and stopped for one week. TAS-102 （25 mg/m²） was taken orally after breakfast and dinner on days 1 to 5 and 8 to 12， with a cycle of 21 days. Data were organized data to analyze the objective response rate （ORR）， disease control rate （DCR）， adverse reactions of the two groups， and patients were regularly followed up to observe their progression free survival （PFS）. Results Until the end of follow-up （March 20， 2023）， the ORR and DCR of the control group were 11.11%， 33.33%， and the median PFS was 6.2 months. The objective response rate of the observation group was 25.00%， white DCR was 83.33%， and median PF was 8.6 months. There was no significant difference in 0RR between the two groups，while the differences in DCR and PFS were statistically significant. The main adverse reactions in both groups were rash， liver dysfunction， gastrointestinal ulcers， hypothyroidism， and oral ulcers. The adverse reactions in both groups were mild. Compared with the control group， 3 patients in the observation group had abdominal pain， which was relieved after drug reduction， and 8 patients had 1-2 levels of bone marrow depression， which recovered after colony-stimulating factor treatment. Conclusions Compared with PD1 inhibitor combined with furoquantinib， the combination of TAS102 on this basis can prolong the survival period of patients with advanced colorectal cancer and tolerate adverse reactions. This regimen has the potential to become a new strategy for the third line treatment of advanced colorectal cancer.

Key words: furoquantinib, PD1 inhibitor, TAS-102, colorectal cancer